O-GlcNAcylation of proteins regulates important cellular processes. A few reports noted that O-GlcNAcylation exhibits cross-talk with tyrosine phosphorylation. With an activity-based microarray analysis of 256 tyrosine kinase peptide substrates, we found that phosphorylation of six peptides by Jak2 inhibits their subsequent O-GlcNAcylation. However, O-GlcNAcylation has no detectable effect on their subsequent phosphorylation. A specific peptide (ZO3_357_371), derived from the ZO-3 protein, was studied in detail. Kinetic results show that the presence of a phosphate at Tyr364 of ZO3_357_371 slows the O-GlcNAcylation of nearby Ser369, while the presence of a GlcNAc at Ser369 has no significant effect on the phosphorylation of this peptide at Tyr364. These findings provide a glimpse into the new paradigm for cellular signaling control by cross-talk.
Given the fact that the O-GlcNAc cycle is controlled by only two enzymes, other mechanisms including cross-talk between PTMs may contribute to the regulation of O-GlcNAcylation of proteins and the related signal processing. O-GlcNAcylation was already found to regulate important cellular processes by cross-talk with phosphorylation and ubiquitination, such as transcription, signaling transduction [11] and protein degradation [12] . O-GlcNAcylation occurs at Ser or Thr residues that may be phosphorylation sites or in close proximity to phosphorylation sites. Therefore, O-GlcNAcylation is competitive with phosphorylation and may play an antagonistic role in the regulation of phosphorylation controlled protein activity and signaling [13] [14] [15] [16] [17] . Proteomic and mass spectrometry analyses have suggested that the cross-talk between O-GlcNAcylation and phosphorylation is very complex and extensive [18, 19] . Recently, a phosphoproteome analysis of known O-GlcNAc proteins showed that 68% of these proteins are known to be substrates of protein tyrosine kinases (PTK) [20] . This suggests that O-GlcNAcylation does not only compete with serine/threonine phosphorylation but that there may also be cross-talk with tyrosine phosphorylation. Although a variety of proteins has been found to be O-GlcNAcylated close to a tyrosine phosphorylation site, whether they can affect each other remains unknown. However, it is still challenging to study the effect of one PTM on the addition of other PTMs in living systems [21] . Naturally, it is possible to study cross-talk of PTMs through gene mutations in living cells, but the complex natural context makes it difficult to draw direct and firm conclusions. Alternatively, direct study of cross-talk can be achieved using semisynthetic whole proteins with PTMs in vitro [21] , but it requires cautious synthesis and may involve protein folding issues.
Here, we describe the utility of an activity-based peptide microarray strategy to identify and directly study cross-talk between O-GlcNAcylation and tyrosine phosphorylation. The relevance of the use of peptides to acquire information about their parent proteins has been shown on numerous occasions for kinases [22] , phosphatases [23] and nuclear receptor coregulators [24, 25] . We can select relevant peptides derived from proteins that are actively being modified by PTMs, and study them directly and in real time [26] . In the present work, we first identified OGT substrates from an array of known tyrosine kinase peptide substrates. Then, the effect of prior O-GlcNAcylation on the subsequent tyrosine phosphorylation was determined, and vice versa. We found that the Jak2-mediated tyrosine phosphorylation of six peptides prevented their own O-GlcNAcylation by OGT, whereas no correlation in the other direction was observed. Amino acid replacement analysis showed that one of these peptides, the ZO-3_357-371 peptide (derived from the ZO-3 protein) is O-GlcNAcylated at Ser369, near the Tyr364 phosphorylation site. Synthetic phosphorylation at Tyr364 of the ZO-3 peptide slowed down the O-GlcNAcylation at Ser369, while synthetic O-GlcNAcylation at Ser369 had no effect on phosphorylation of Tyr364. Molecular modeling suggests that the phosphorylation of Tyr364 may lead to the loss of a hydrogen bond of the substrate with Asn805 of OGT and also lead to a steric clash and repulsive interactions. In the opposite case, it was clear that OGlcNAcylation site Ser369 of the ZO-3 peptide is not in contact with Jak2, whether it is O-GlcNAcylated or not. Finally, we observed a similar cross-talk effect when a HeLa cell lysate was used as the source of OGT activity and protein tyrosine kinase activity on this peptide and its modified forms. These results further enhance our understanding of cross-talk between O-GlcNAcylation and phosphorylation and the molecular mechanism with which they can affect cellular signaling control. 
Materials and methods

Materials
Cell culture
HeLa cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 unitsÁmL À1 penicillin and 100 lgÁmL À1 streptomycin). Cells were cultured in an incubator with a humidified atmosphere containing 5% CO 2 at 37°C. After cells were grown to a confluence of 80%, media was removed and cells were washed three times with precold PBS. Cells were then scrapped in precold M-PER Mammalian Extraction Buffer supplemented with Halt Protease Inhibitor Cocktail, and 50 lM OGA inhibitor (PUGNAc). After incubating 30 min on ice, the lysate was centrifuged for 15 min at 16 000 g at 4°C. The supernatant was transferred into a clean tube and stored at À80°C.
Protein expression and purification
A plasmid encoding OGT was a generous gift from John A. Hanover (National Institute of Health, USA). The plasmid was transformed into Escherichia coli BL21 (DE3) competent cells to produce a cell lysate containing OGT. One-step purification was performed using His60 Ni Gravity Flow Columns (Clontech, Mountain View, CA, USA) according to the manufacturer's instructions. The nickel column was equilibrated with a buffer containing 50 mM sodium phosphate, 300 sodium chloride, 20 mM imidazole, and pH 7.4, followed by incubation with cell lysate containing His tag OGT for 1 h at 4°C. After washing several times using buffer containing 50 mM sodium phosphate, 300 sodium chloride, 40 mM imidazole, and pH 7.4, the recombinant OGT was eluted using elution buffer containing 50 mM sodium phosphate, 300 sodium chloride, 300 mM imidazole, and pH 7.4. The eluted fraction was concentrated through a 100 000 Da molecular weight cut off Amicon unit by centrifugation at 3438 g at 4°C.
Solid-phase peptide synthesis and LC-MS analysis
Synthesis of all the peptides was performed by following a standard Fmoc SPPS strategy with a symphony Multiple Peptide Synthesizer (Protein Technology, Tucson, AZ, USA) and starting from 50 mM Rink amide resin. All standard Fmoc amino acids used were commercially available except for Fmoc-Ser-(Ac 3 -GlcNAc)-OH, which was prepared in our lab according to a literature procedure [27] .
Coupling of all Fmoc amino acids was achieved using 0.16 M benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate and 0.16 M diisopropylethylamine in dimethylformamide (DMF), whereas deprotection of Fmoc was performed using 20% piperidine in DMF. DMF and dichloromethane (DCM) were used as washing solvents. After completion of the synthesis, the protected peptidyl resins were cleaved by using a 10 mL mixture of trifluoroacetic acid: H 2 O: triisopropylsilane: 1,2-ethanedithiol (9 : 0.5 : 0.25 : 0.25, v/v/v/v) and allowed to stir for 4 h at room temperature under a nitrogen atmosphere. Before cleavage of the glycopeptide from the resin, the acetyl protecting groups on GlcNAc were removed by treating the peptidyl resin with sodium methoxide in dry methanol (pH > 9) overnight. To deprotect the phosphotyrosine, after cleavage from the resin, 10% by volume of water was added into the cleavage solution and then stirred at room temperature overnight. The cleaving mixture was filtered and the resin was washed with TFA and DCM. The peptides were precipitated by treatment of precooled diethyl ether and centrifugation. Three times washing and centrifugation yielded the crude products in a pellet. The precipitated peptides were dissolved in water, frozen, and lyophilized. The purity of peptide was analyzed using liquid chromatography-mass spectrometry (LC-MS).
Microarray assay for OGT and tyrosine kinase
A microarray assay was performed using PamChip 4 microarray chips with a PamStation 12 instrument (Pamgene international). The OGT reaction was prepared essentially as described [28] with minor modifications. Briefly, before addition of the enzyme reaction, the microarray was blocked with 1% BSA. After 30 cycles (2 cyclesÁmin À1 ) blocking, the blocking buffer was aspirated and the microarray was incubated with 40 lL of the enzyme reaction containing purified OGT (2 lg), reaction buffer (50 mM Tris-HCl, pH 7.5; 1 mM DTT; 12.5 mM MgCl 2 ), a 1 : 1 preincubated mixture of anti-O-GlcNAc and FITCconjugated secondary antibody, and the sugar donor UDPGlcNAc for 2 h at 30°C. To pre-O-GlcNAcylate the microarray for studying cross-talk, the OGT reaction was prepared just without antibody and incubated with microarray for 16 h. The kinase reaction was performed according to the Pamgene PTK-assay user manual. Briefly, after blocking the microarray with 1% BSA, the microarray was incubated with 40 lL of kinase reaction containing PK buffer (50 mM Tris-HCl, 10 mM MgCl 2 , 0.1 mM EDTA, 2 mM DTT, 0.01% Brij35, pH 7.5), purified Jak2 (0.5 lg)/ABL1 (0.5 lg)/Ret (0.5 lg) proteins, fluorescein-labeled PY20 antibody and ATP for 2 h at 30°C. To prephosphorylate the microarray for studying cross-talk, the kinase reaction was prepared just without antibody and incubated for 16 h.
The microarray was run in parallel by pumping the reaction up and down through the porous membrane and a tiff image was obtained at every 20 cycles by a CCD camera inside the PamStation. Modification of each peptide was detected by a fluorescent signal which was produced by a FITC-conjugated antibody bound to the O-GlcNAc or phosphotyrosine moiety on the peptide. Image analysis was performed using the BIONAVIGATOR 6 software (Pamgene International, 's-Hertogenbosch, the Netherlands). Briefly, each image was quantified by automated array grid finding and subsequent quantification of signal and local background for each individual spot. In this work, the signal median-minus-background value was used as the quantitative parameter for the O-GlcNAcylation of the peptide.
UDP-Glo assay
In this work, OGT activity was also determined using the UDP-Glo TM Glycosyltransferase Assay (Promega, Madison, WI, USA) according to the manufacturer's instructions. This assay evaluates O-GlcNAcylation through monitoring UDP formation in glycosyltransferase reactions by luminescence. Briefly, OGT reactions were carried out in 12.5 lL final volume containing UDP-GlcNAc (200 lM), purified OGT (2 lg) and peptide (200 lM) in OGT reaction buffer (50 mM TrisHCl, pH 7.5; 1 mM DTT; 12.5 mM MgCl 2 ). Reactions were incubated at room temperature for 2 h. At the end of that period, each reaction was transferred into a 96-well white microplate and was mixed with a 1 : 1 ratio of UDP-Glo detection reagent. After incubation at room temperature for 1 h, the luminescence was recorded with a POLARstar Omega microplate reader.
ADP-Glo assay
In this work, kinase activity was also determined using the ADP-Glo TM Kinase Assay (Promega) according to the manufacturer's instructions. The ADP-Glo assay measures the byproduct ADP from a kinase reaction. Briefly, the kinase reaction was carried out in 12.5 lL of PK buffer (50 mM Tris-HCl, 10 mM MgCl 2 , 0.1 mM EDTA, 2 mM DTT, 0.01% Brij35, pH 7.5), ultrapure ATP (200 lM), purified Jak2 (0.5 lg)/ABL1 (0.5 lg), Ret (0.6 lg), PTK additive and peptide (200 lM) in 96-well plates. After incubation at room temperature for 2 h, ADP-Glo reagent (12.5 lL per well) was added into each well and the reaction was incubated at room temperature for 40 min to terminate the reaction and deplete the remaining ATP. The kinase detection reagent (25 lL per well) was then added and the reaction was incubated at room temperature for 40 min to convert the byproduct ADP to ATP. The newly synthesized ATP was further determined by using luciferase and luciferin reaction. The luminescence was recorded with a POLARstar Omega microplate reader.
Homology modeling of the human OGT-ZO-3 peptide complex
Completeness of the OGT structure (PDB entry: 4GYW) was improved by homology modeling to model the missing and incomplete residues using Prime (Schr€ odinger Release 2016-3: Prime, Schr€ odinger, LLC, New York, NY, 2016). Ten models were generated and the best model for further studies was selected based on the stereochemical quality of the model as evaluated by PROCHECK [29] and ProSAweb server [30, 31] .
A homology model of the ZO-3 peptide (YDIYR VPSSQS) was built based on the conformation of the glycopeptide from the crystal structure of OGT-glycopeptide complex (PDB entry: 4GYW). Amino acid sequences were manually aligned by correctly aligning Ser residues which were shown to be O-GlcNAcylated (Fig. S4A) . A homology model of the shorter ZO-3 peptide (YDIYRVPSSQS) than used in the study (CGRESSYDIYRVPSSQS) was built, since for the missing part no template was available in the PDB. Tyr364 of the ZO-3 peptide was then mutated to phosphotyrosine to give the phosphorylated ZO-3 peptide.
Homology models of OGT and ZO-3 peptide or phosphorylated ZO-3 peptide were combined to yield to complexes, which were refined further using the Protein Preparation Wizard (Schr€ odinger Release 2016-3: Schr€ odinger, LLC, New York, NY, 2016). Hydrogen atoms were added, bond orders assigned and hydrogen bonds assigned by sampling water orientations at pH 7.4 using PROPKA. The complex was further optimized by restrained minimization by setting converge heavy atoms to RMSD parameter to 0.5 A.
Building of the Jak2 kinase-ZO-3 peptide complex
A crystal structure of insulin receptor tyrosine kinase (IRK) in complex with peptide substrate (PDB entry: 1IR3) [32] was used as a template to build the Jak2 kinase-ZO-3 peptide complex. Crystal structures of Jak2 kinase (PDB entry: 4GFM) [33] and IRK (PDB entry: 1IR3) were superimposed based on sequence alignment and three-dimensional structure similarity. ZO-3 peptide was then superimposed with the peptide from the IRK crystal structure. The superimposition was guided by correctly overlaying the Tyr residues that are being phosphorylated by the tyrosine kinases. The Jak2 kinase-ZO-3 peptide complex obtained was refined further using the Protein Preparation Wizard (Schr€ odinger Release 2016-3: Schr€ odinger, LLC, New York, NY, 2016). Hydrogen atoms were added, bond orders assigned and hydrogen bonds assigned by sampling water orientations at pH 7.4 using PROPKA. The complex was further optimized by restrained minimization by setting converge heavy atoms to RMSD parameter to 0.5 A.
Molecular dynamics
The molecular dynamics package NAMD (version 2.11) [34] and CHARMM22 force field [35] were used for molecular dynamics simulations of OGT-ZO-3 peptide and OGT-phosphorylated ZO-3 peptide complexes. The structure of the complex for MD simulation was prepared using psfgen in VMD (version 1.9.2.) [36] . The complex was then embedded in a box of water, which was modeled explicitly by a TIP3P model [37] . The system was neutralized by addition of NaCl. The MD simulation was carried out in the NPT ensemble employing periodic boundary conditions. Langevin dynamics and Langevin piston methods were used for temperature (300 K) and pressure (1 atm) control, respectively. Shortand long-range forces were calculated every 1 and 2 time steps, respectively, with a time step of 2.0 ps. The smooth particle mesh Ewald method [38] was used to calculate electrostatic interactions. The short-range interactions were cut off at 12 A. All chemical bonds between hydrogen and heavy atoms were held fixed using the SHAKE algorithm [39] . The simulation consisted of three consecutive steps: (a) solvent equilibration for 1 ns with (phosphorylated) ZO-3 peptide and OGT protein constrained harmonically around the initial structure, (b) equilibration of the complete system for 1 ns with (phosphorylated) ZO-3 peptide and protein released, and (c) an unconstrained 10 ns production run to allow the protein and (phosphorylated) ZO-3 peptide to position themselves according to physical forces between them. The trajectory of the equilibration and production run was used for analysis in VMD.
Results
Identification of novel OGT substrates from tyrosine kinases peptide substrates
To identify novel cross-talk between O-GlcNAcylation and tyrosine phosphorylation, we first tried to identify peptides that can both be modified by Jak2 and OGT using a dynamic peptide microarray containing 256 peptides derived from tyrosine kinase substrate proteins ( Fig. 1A and Table S1 ). The phosphorylation of the peptides was determined by incubating the microarray with Jak2, ATP, and a FITC-conjugated anti-phosphotyrosine antibody, while the O-GlcNAc modification of the peptides was determined by incubating the microarray with OGT, the sugar donor UDP-GlcNAc, and a 1 : 1 preincubated mixture of anti-O-GlcNAc and FITC-conjugated secondary antibody [40] . Among these tyrosine kinase peptide substrates, it was previously determined that 201 peptides were Jak2 substrates and 10 peptides were OGT substrates (Fig. 1B and Table S1 ). Interestingly, seven of these OGT substrates can also be modified by Jak2, indicating the potential for cross-talk between OGlcNAcylation and tyrosine phosphorylation.
The effect of tyrosine phosphorylation by Jak2 on O-GlcNAcylation by OGT
To study the cross-talk between O-GlcNAcylation and tyrosine phosphorylation, we reprinted these OGT peptide substrates on a new microarray. The microarray was exposed to Jak2 tyrosine kinase, and then the O-GlcNAcylation of these peptides was determined by the mentioned OGT assay using fluorescence antibody detection. (Figs 2 and S2A) . Prephosphorylation of ABLM1_350_364, ABLM1_ 454_468, CBL_667_681, GAB1_252_266, SCAM3_ 79-93, and ZO3_357_371 resulted in a significant reduction of O-GlcNAcylation (Fig. 2) . Similar effects on O-GlcNAcylation were seen when the ABL1 and Ret kinases were used (Figs S1 and S2).
The effect of O-GlcNAcylation on tyrosine phosphorylation
In the other direction, the peptides were pre-O-GlcNAcylated using OGT and its effect on tyrosine Jak2 phosphorylation was determined using fluorescence antibody detection (Figs 3 and S3A) . It was found, most notably for the six mentioned peptides that showed cross-talk in the other direction, that preGlcNAcylation had no detectable effect on the subsequent phosphorylation of these peptides. Similarly, the O-GlcNAcylation had no significant effect on the phosphorylation of these peptides by the ABL1 and Ret kinases either (Fig. S3) . All values are mean AE SD from three independent replicates. Statistical analysis was performed using the t-test. P < 0.001(*) is considered as a substrate and NS, not significant.
ZO-3 is O-GlcNAc modified at Ser369 and phosphorylated at Tyr364
Since the O-GlcNAcylation of ZO-3_357-371 peptide, derived from the ZO-3 protein, was the most strongly affected by its tyrosine phosphorylation, we decided to identify the O-GlcNAc modification site on this peptide. This was done in order to further validate the site-specific cross-talk. For this purpose, we prepared the ZO-3_357-371 wild-type peptide and a series of mutants in which the individual serines and tyrosines were replaced by alanines and phenylalanines, respectively (Fig. 4 ). An extra Cys-Gly dipeptide was added onto the N terminus of these peptides to enable the thiol-based immobilization on the array. The phosphorylation of these mutants was determined using the mentioned Jak2 microarray assay. As shown in Fig. 4A , substitution of Tyr364 with Phe resulted in an 85% reduction of Jak2 activity, indicating that Tyr364 is the major site of phosphorylation of this peptide. The phosphorylation of Tyr364 was also the predicted site based on the consensus motif for Jak2 substrates (Fig. S5) [41] . The O-GlcNAcylation of these peptides was determined using the mentioned OGT microarray assay. With these mutants, we found that S369A led to a complete loss of OGT activity for this peptide (Fig. 4B) , indicating that it was indeed Ser369 that was modified by O-GlcNAc in the ZO-3_357-371 peptide. This peptide showed the highest activity among all tested peptides in our experiments and it strongly matched the reported consensus motif for O-GlcNAcylation (Fig. S5) [42] [43] [44] [45] .
Phosphorylation of ZO-3 at Tyr364 antagonizes its O-GlcNAcylation at Ser369
To study the site to site interaction between O-GlcNAcylation and phosphorylation on the ZO-3_357-371 peptide, a Tyr364 phosphorylated peptide (Y364p) and a Ser369 GlcNAcylated peptide (S369g) were Fig. 2 . The effect of tyrosine phosphorylation on O-GlcNAcylation. The microarray was incubated with the Jak2 tyrosine kinase (no detection antibody) with ATP in various concentrations, Pre-Jak2 (À), 0 mM; Pre-Jak2 (+), 0.4 mM; Pre-Jak2 (++), 0.8 mM for 16 h. After washing three times with TBS, the same microarray was incubated with OGT (visualization by the RL2 O-GlcNAc antibody) with UDPGlcNAc [OGT (À), 0 mM; OGT (+), 0.5 mM] for 2 h. After quantification, a heat map was shown for the effect of phosphorylation of each peptide on its O-GlcNAcylation. All values are mean AE SD from three independent replicates. Statistical significance was determined using one-way analysis of variance (ANOVA). Significant difference (P < 0.05) of OGT (+) activity between Pre-Jak2 (À) and Pre-Jak2 (+) was considered as a cross-talk. After washing three times with TBS, the microarray was incubated by Jak2 tyrosine kinase (visualization by the PY20 phosphotyrosine antibody) with ATP [Jak2 (À), 0 mM; Jak2 (+), 0.4 mM] for 2 h. After quantification, a heat map was shown for the effect of O-GlcNAcylation of each peptide on its phosphorylation. All values are mean AE SD from three independent replicates. Statistical significance was determined using one-way analysis of variance (ANOVA). Significant difference (P < 0.05) of Jak2 (+) activity between Pre-OGT (À) and Pre-OGT (+) was considered as cross-talk.
synthesized. The O-GlcNAcylation of Y364p peptide by OGT was determined by using the UDP-Glo assay, which measures UDP production. Similarly, phosphorylation of S369g peptide by Jak2 was determined using the ADP-Glo assay, measuring ADP. Phosphorylation at Tyr364 caused an 80% reduction of the subsequent OGT activity on this peptides (Fig. 5A) , while O-GlcNAcylation at Ser369 did not show a significant effect on the subsequent phosphorylation by Jak2 (Fig. 5B) . This was confirmed by using the microarray assay with immobilized peptides. As shown in Fig. 5C ,D, kinetic reading of the signal indicated that the phosphate group at Tyr364 of this peptide significantly slowed down its O-GlcNAcylation by OGT, while the O-GlcNAcylation of this peptide at S369 had no effect on its phosphorylation by Jak2.
In addition, we observed a clear cross-talk effect on these peptides when a HeLa cells lysate was used as the source of OGT and tyrosine kinases, although the cell lysate showed only a moderate OGT and tyrosine kinase activity (Fig. 5E,F) . Together, these data indicate that phosphorylation of ZO-3 at Tyr364 hinders its O-GlcNAcylation at Ser369, while the initial Ser369 O-GlcNAcylation does not influence the Tyr364 phosphorylation. Somehow the phosphate group on the Tyr364 must make the access of the nearby Ser369 more difficult for O-GlcNAcylation.
Homology modeling and molecular dynamics simulations of the OGT-ZO-3 peptide complexes
To obtain more mechanistic insights into the observed cross-talk involving the ZO-3 peptide, we modeled the effect of the phosphate modifications on the binding of the ZO-3 peptide to OGT. The high-resolution crystal structure of OGT in complex with UDP and a glycopeptide [46] was taken as a starting point for modeling the potential binding mode of the ZO-3 peptide in the OGT peptide-binding site. Homology modeling was used to improve the completeness of the OGT crystal structure and to build models of the ZO-3 peptide (YDIYRVPSSQS) and phosphorylated version. The obtained models of OGT-ZO-3 peptide and OGT-phosphorylated ZO-3 peptide complexes were further studied by molecular dynamics simulations to evaluate their structural stability and to study the possible differences in the peptide-binding modes, which would rationalize the experimental data. Physical stability of the simulations was monitored by temperature, volume and total energy vs. time plots. All these parameters of the system were stable during the production run of the simulation. Structural stability of the system during the simulation was monitored by measuring the RMSD values of protein backbone atoms during the simulation (Fig. S4) .
Binding of the (phosphorylated) ZO-3 peptide to human OGT
Analysis of the potential binding mode of the ZO-3 peptide to the human OGT peptide-binding site showed that Ser369 of the ZO-3 peptide is oriented in a way that enables O-GlcNAcylation (Fig. S4B) . The complex showed structural stability during an 11 ns MD simulation (equilibration and production run) (Fig. S4C,D and Movie S1). An average RMSD value of the human OGT backbone atoms was 2.2 A (Fig. S4C) , while the backbone atoms of the ZO-3 peptide had a higher average RMSD value of 3.2 A (Fig. S4D) . Before the MD simulation, the phosphorylation site, (Tyr364) hydroxyl group of the ZO-3 peptide forms a hydrogen bond with the OGT Asn805 side chain and is in the proximity of the negatively charged Glu811 (Fig. S4B) . After the 11 ns MD simulation the conformation of the Arg365 side chain of the ZO-3 peptide is changed to enable salt bridge formation with Asp587 of OGT (Fig. 6A) . This influences the binding interactions between the N-terminal part of the ZO-3 peptide and OGT residues. For example, the hydrogen bond between Tyr364 and Asn805 is lost, while the position and conformation of Glu811 remains almost unchanged. Upon phosphorylation of the Tyr364 residue, a similar loss of a hydrogen bond with Asn805 is expected (Figs 6B and S4E) as well as a possible steric clash and repulsive interactions with Glu811, which could prevent the O-GlcNAcylation of Ser369. While an average RMSD of 2.0 A of the OGT backbone atoms remained reasonably low (Fig. S4F) , the average RMSD value of the phosphorylated ZO-3 peptide backbone atoms increased to 4.2 A (Fig. S4G) . In particular, the N-terminal part of the ZO-3 peptide loses contacts with the protein and is oriented toward the solvent. The phosphorylated Tyr364 side chain forms an intramolecular ionic interaction with the adjacent Arg365 (Fig. 6B) , which results in the loss of a salt bridge formation between the peptide residue Arg365 and Asp587 of OGT and finally in a weaker binding of the peptide as also indicated by its higher conformational fluctuations reflected by the increased RMSD (Fig. S4F,G and Movie S2).
Modeling the binding of ZO-3 peptide to Jak2 kinase
Since there is no crystal structure of Jak2 kinase in complex with a peptide substrate available in the Protein Data Bank, the insulin receptor tyrosine kinase (IRK) in complex with a peptide substrate (PDB entry: 1IR3) [32] was used as a starting point. First, the Jak2 kinase (PDB entry: 4GFM) [33] and the IRK crystal structures were superimposed in order to identify the Jak2 kinase peptide-binding site, in particular the binding site of the Tyr residue that is the site of phosphorylation (Fig. S4H) . The ZO-3 peptide was then superimposed with the peptide from the IRK crystal structure. The Jak2 kinase-ZO-3 peptide complex obtained in this way shows that O-GlcNAcylation of Ser369 in the ZO-3 peptide should not prevent the phosphorylation of Tyr364 of the ZO-3 peptide, since Ser369 is placed in the solvent and is not in contact with the Jak2 kinase residues (Fig. 6C ).
Discussion
Here, we employed an activity-based peptide microarray approach to study the potential cross-talk between O-GlcNAcylation and tyrosine phosphorylation. The experimentally identified OGT peptide substrates from known tyrosine kinase substrates were used to study the direct cross-talk between O-GlcNAcylation and tyrosine phosphorylation. Using kinases Jak2, ABL1 and Ret to prephosphorylate the identified OGT substrates inhibited the subsequent O-GlcNAcylation of six peptides. The reverse analysis measuring the effect of O-GlcNAcylation on tyrosine phosphorylation of these peptides revealed no detectable correlation. Using HeLa cells as the source of the enzymes showed the same results. A specific peptide (ZO3_357_371) was studied in more detail which confirmed the results of the microarray.
Finally, modeling analysis indicated that the phosphorylation of Tyr364 may lead to the loss of a hydrogen bond between Tyr364 of the peptide substrate and Asn805 of OGT as well as introduce a steric clash and repulsive interactions, which could prevent the O-GlcNAcylation of Ser369. However, the model of the kinase Jak2 in complex with the peptide showed that Ser369 of the peptide is not in contact with Jak2. As a result, O-GlcNAcylation of Ser369 should not affect binding of the peptide to Jak2 and further phosphorylation, thus confirming the experimental result.
Accordingly, these results filled a gap in our knowledge of cross-talk between O-GlcNAcylation and tyrosine phosphorylation and we propose that tyrosine phosphorylation may have a significant contribution to the dynamic regulation of O-GlcNAc cycling, while O-GlcNAc has less impact on phosphorylation signaling. Interestingly, in four of the six identified cases of cross-talk the distance between the predicted modified tyrosine and serine/threonine sites is five amino acids, and one and six in the other two. The fact that the Jak2 tyrosine is not affected by O-GlcNAcylation of nearby residues is consistent with its known sequence preferences which only contains the area between the 1-3 and i + 3 residues relative to the modified tyrosine, none of which were serines or threonines in the cases of the identified duals substrate peptides.
The use of a microarray was instrumental as it allowed the rapid identification of OGT substrates among tyrosine kinase substrates. Furthermore, it allowed us to zoom in on specific sequences quickly, chemically introduce the phosphate and GlcNAc group at will at specific positions and study the consequences of their presence. This level of precision combined with the speed, makes the tool particular useful. Taken together, this study reports the utility of an activity-based peptide microarray approach to study the cross-talk between O-GlcNAcylation and tyrosine phosphorylation. These sequences in the respective proteins can be the starting point for cell based studies aimed at unraveling this complex mechanism. Further studies using this approach may advance our understanding of the role of signaling regulation by cross- talk between O-GlcNAcylation and tyrosine phosphorylation.
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